Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Cyclophosphamide × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 491 Triple Negative Breast Neoplasms 77 Inflammatory Breast Neoplasms 29 Breast Neoplasms, Male 26 Neoplasm Metastasis 23 Ovarian Neoplasms 21 Carcinoma, Non-Small-Cell Lung 21 Melanoma 20 Neoplasms 14 Pancreatic Neoplasms 13 Colorectal Neoplasms 12 Carcinoma, Renal Cell 11 Stomach Neoplasms 10 Multiple Myeloma 10 Lung Neoplasms 9 Carcinoma, Ovarian Epithelial 9 Lymphoma, Non-Hodgkin 8 Carcinoma, Hepatocellular 8 Sarcoma 7 Lymphoma, Follicular 7 Lymphoma 7 Recurrence 6 Neutropenia 6 Lymphoma, Mantle-Cell 6 Lymphoma, Large-Cell, Immunoblastic 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, B-Cell, Marginal Zone 6 Leukemia, Myeloid, Acute 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Kidney Neoplasms 6

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡